Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis (EU-20619)

Titre officiel

Phase III Study of Induction and Maintenance Therapy Comprising Etoposide, Dexamethasone, and Cyclosporine Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Primary Inherited or Severe and Persistent Secondary Hemophagocytic Lymphohistiocytosis

Sommaire:

Les médicaments utilisés pour la chimiothérapie agissent de différentes façons pour stopper la multiplication des cellules dans la lymphohistiocytose hémophagocytaire, soit en les tuant soit en les empêchant de se diviser. L’administration d’un traitement d’association permet de tuer un plus grand nombre de ces cellules. Grâce à une allogreffe de cellules souches, il est possible de remplacer les cellules hématopoïétiques qui ont été détruites par la chimiothérapie. Il arrive parfois que les cellules greffées provenant d’un donneur aient une réponse immunitaire contre les cellules normales du patient greffé. L’administration de cyclosporine et de méthotrexate peut empêcher que cela ne se produise.

Cet essai de phase III vise à déterminer l’efficacité d’une polychimiothérapie suivie d’une allogreffe de cellules souches dans le traitement des patients atteints de la lymphohistiocytose hémophagocytaire.

Description de l'essai

Primary Outcomes

  • Provide and evaluate revised induction and maintenance therapy comprising etoposide, dexamethasone, and cyclosporine, in terms of achieving and maintaining an acceptable clinical condition in order to perform a curative allogeneic hematopoietic stem cell transplantation (AHSCT), in patients with primary inherited or severe and persistent secondary hemophagocytic lymphohistiocytosis (HLH).
  • Evaluate and improve the outcome of AHSCT with various types of donors.
  • Determine the prognostic importance of the state of remission at the time of AHSCT.
  • Evaluate the neurological complications, in terms of early neurological alterations and cerebrospinal fluid (CSF) findings, in patients treated with this regimen.

Secondary Outcome: Improve the understanding of the pathophysiology of HLH by conducting biological studies of genetics and cytotoxicity in these patients, including genotype-phenotype studies and the prognostic value of natural killer cell activity subtyping.  

This is a multicenter study. Patients receive etoposide IV over 1-3 hours twice weekly in weeks 1 and 2 and then once weekly in weeks 3-8. Patients also receive dexamethasone IV or orally once daily and cyclosporine IV or orally twice daily in weeks 1-8. Patients with clinically evident, progressive neurological symptoms or an abnormal CSF that has not improved after 2 weeks of induction therapy undergo intrathecal therapy comprising methotrexate and hydrocortisone once weekly in weeks 3-6. 

Patients are evaluated after 8 weeks of induction therapy. Patients with primary HLH or genetic evidence of HLH proceed to maintenance therapy. Patients with severe and persistent secondary HLH and no genetic evidence of HLH proceed to maintenance therapy only if their disease is still active after induction therapy. Patients with nonfamilial HLH and no genetic evidence of HLH who have achieved complete remission discontinue treatment. If their disease reactivates, they may then proceed to AHSCT. 

Patients receive dexamethasone IV on days 1-3 in weeks 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, and 40; etoposide IV over 1-3 hours once in weeks 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, and 39; and cyclosporine IV or orally twice daily in weeks 9-40.

After completion of maintenance therapy, patients with primary (i.e., familial) HLH, severe and persistent secondary HLH, or reactivating disease proceed to AHSCT. Patients with nonfamilial HLH who have completed maintenance therapy, but do not go on to receive AHSCT, may be recommended for additional maintenance therapy at the discretion of the treating physician.  

Preparative regimen: Patients receive a preparative regimen comprising busulfan orally or IV four times daily on days -8 to -5, etoposide IV over 6 hours on day -4, and cyclophosphamide IV over 1 hour on days -3 and -2. Patients who are undergoing unrelated AHSCT, also receive antithymocyte globulin IV over 12 hours on days -3 to -1.

  • Transplantation: Patients undergo AHSCT on day 0.
  • Beginning on day -1, patients receive cyclosporine IV continuously and then orally, when tolerated, once daily for 6-12 months. Patients also receive methotrexate* IV on days 1, 3, and 6.

Patients undergo periodic blood collection and bone marrow biopsies for biological studies. After completion of study treatment, patients are followed periodically for up to 5 years.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer